1. Introduction {#s0005}
===============

Aminoacidurias are caused by defective amino acid transport across the renal epithelium. Inborn errors of amino acid transporters include lysinuric protein intolerance (LPI) (MIM \#[222700](222700){#ir0005}), cystinuria (MIM \#[220100](220100){#ir0010}), iminoglycinuria (MIM \#[242600](242600){#ir0015}), dicarboxylic amino aciduria (MIM \#[222730](222730){#ir0020}) and Hartnup disorder (MIM \#[234500](234500){#ir0025}). Next to defective amino acid transporters, transport of amino acids can also be impaired by general dysfunction of the renal tubule, as occurs for example in Fanconi syndrome \[[@bb0025]\] and Lowe syndrome \[[@bb0040]\]. Aminoacidurias are biochemically classified according to their specific amino acid excretion pattern.

Hartnup disorder has an estimated frequency of 1:20.000 \[[@bb0045]\] and is caused by a deficiency of the sodium dependent B^0^ AT1 neutral amino acid transporter, encoded by *SLC6A19*. This transporter is mainly expressed in the brush border membrane of the proximal kidney tubules and in the jejunum \[[@bb0035],[@bb0060],[@bb0065]\]. The disorder is biochemically characterized by increased excretion of neutral amino acids including alanine, serine, threonine, valine, leucine, isoleucine, phenylalanine, tyrosine, asparagine, glutamine, tryptophan, histidine and citrulline, whereas excretion of other amino acids is reported to be less affected (Nanto-Salonen et al. 2006, Vademecum Metabolicum).

The impaired renal and intestinal transport of neutral amino acids is a risk factor for developing amino acid deficiencies, tryptophan deficiency in particular. As tryptophan is the precursor for serotonin and nicotinamide, also known as vitamin B3, the clinical symptoms of Hartnup disorder are those of a nicotinamide deficiency. Reported symptoms include dermatological symptoms, particularly a pellagra-like rash and light-sensitive dermatitis, intermittent cerebellar ataxia and psychiatric symptoms as emotional instability, delirium and hallucinations \[[@bb0015]\]. All symptoms respond well to treatment with vitamin B3 \[[@bb0075]\].

To date, many individuals remain asymptomatic \[[@bb0070]\], likely because of a sufficiently high intake of protein, tryptophan, vitamin B3 or a combination thereof \[[@bb0015]\]. However, even in asymptomatic patients, accurate diagnosis of Hartnup disorder is essential \[[@bb0020],[@bb0070]\], to ensure correct differentiation of Hartnup disorder from other aminoacidurias, which would demand alternative diagnostic trajectories. Biochemically, Hartnup disorder is diagnosed based on the amino acid excretion profile. Here, we demonstrate that patients with Hartnup disorder may present with an amino acid excretion pattern that closely resembles generalized aminoaciduria \[[@bb0010],[@bb0015],[@bb0030]\]. We show that this potential misdiagnosis can be overcome by quantification, visualization and computation of urinary amino acids, enabling us to correctly discriminate Hartnup disorder from other causes of aminoaciduria.

2. Methods {#s0010}
==========

2.1. Patient inclusion {#s0015}
----------------------

Twenty-seven urine samples of 11 patients with Hartnup disorder were analyzed. Four of these patients were included at the University Medical Centre Utrecht. Hartnup disorder was confirmed through PCR amplification followed by Sanger sequencing of *SLC6A19*. Patient 1 is compound heterozygous for the pathogenic *SLC6A19* c.517G\>A (p.Asp173Asn) and c.1173+2T\>G (p.?) mutations \[[@bb0065]\]. Patient 2, 3 and 4 are homozygous for the common *SLC6A19* c.517G\>A (p.Asp173Asn) mutation. Patient 3 and 4 are siblings. To extend the Hartnup disorder cohort, amino acid excretion patterns of seven patients with Hartnup disorder previously published by Potter et al. were included \[[@bb0055]\]. Hartnup disorder was genetically confirmed in these patients by Seow et al. \[[@bb0065]\]. One patient (patient 2/II) was excluded, because of heterozygosity for cystinuria type II. In the patients from Potter et al., amino acid excretion patterns were quantified using a Beckman 6300 amino acid analyzer \[[@bb0055]\].

To differentiate Hartnup disorder from other aminoacidurias, 10 samples of 7 patients with generalized aminoaciduria, 16 samples of 2 patients with LPI and 42 samples of 7 patients with cystinuria were included, coming to a combined aminoaciduria cohort of 68 samples of 16 patients, all from the University Medical Centre Utrecht. All diagnoses were genetically confirmed.

2.2. Quantification of amino acid excretion {#s0020}
-------------------------------------------

Amino acid excretion was quantified at the University Medical Centre Utrecht using a Biochrom amino acid analyzer (Isogen Life Sciences, de Meern, the Netherlands) according to diagnostic standards. Amino acid excretion was expressed in mmol/mol creatinine. Age adjusted reference values were obtained from literature, taking into account seven age groups: first week (1), first week till first month (2), first month till four months (3), four months till two years (4), two years till ten years (5), ten years till eighteen years (6) and above eighteen years (7) \[[@bb0005]\].

2.3. Statistical analysis {#s0025}
-------------------------

Amino acid fold changes were calculated by dividing the quantified excretion values over the upper limit of the age-adjusted reference value. Amino acids were grouped into Hartnup amino acids (HAA) versus other amino acids (OAA). HAA included alanine, serine, threonine, valine, leucine, isoleucine, phenylalanine, tyrosine, asparagine, glutamine, tryptophan, histidine and citrulline (Nanto-Salonen et al. 2006, Vademecum Metabolicum), and OAA included arginine, lysine, aspartic acid, glutamic acid, glycine, cysteine, methionine, proline, ornithine, taurine and alpha-aminobutyric acid. Statistical analyses were performed using R programming language. Results were visualized in both heatmaps and scatter plots. Data files and R code are available upon request.

3. Results {#s0030}
==========

Amino acid excretion patterns of the patients with Hartnup disorder in the Utrecht cohort are presented in [Table 1](#t0005){ref-type="table"}. This table displays that increased excretion of amino acids is not restricted to HAA, but also includes many OAA, including cystine (in all 20 samples), alpha-aminobutyric acid (in 19/20), glycine and lysine (both in 17/20), citrulline and glutamic acid (both in 15/20), aspartic acid (in 14/20) and arginine (in 12/20). This precludes discrimination of Hartnup disorder from other aminoacidurias and induces the risk of misclassification as generalized aminoaciduria ([Fig. 1](#f0005){ref-type="fig"}A).Table 1Amino acid excretion of patients with Hartnup disorder.Table 1Upper limits age groupsPatient 1Patient 2Patient 3Patient 41.11.21.31.41.52.12.22.32.43.13.23.33.43.53.64.14.24.34.44.5Age group0506070505050505070707070505060606070505050506Alanine80855910991443110253996940726447247910266211020968104111084745905854601429Serine957869147120151220724114575453670065515501002110811549979887367458926721631Threonine4536488261180608556734348325455423891724506550564567513376485374854Valine121173441094329381550500560653663605388363338416389441349377243803Leucine12969877614128119325928733219922081117151138181678733189Isoleucine775155510143262131175197229189168888811513119210513550199Phenylalanine201711119353951221561511341611751521288476961011099511037123Tyrosine423727623949536432616299233254249717488377431521272375327436231656Asparagine29279760972520569317316437357504382417430389388355441312492Glutamine1379857265846843176119018731571185912571793300914221858156020301443105211971272997879Histidine216184153836125973280443642439644358710602656640515489557587477713Citrulline185238134349054514453505023311814821826Arginine98714578183411688914911661125211Lysine642052237751154202359675980103118208577059578737403284Aspartic acid217547344012152342422634182919264319Glutamic acid316363258731078917888622622316512623620313735Glycine201252199562739377297488224111169195475365437647718730334309356311877Cysteine1716192471222634653145466660282421203220262540Ornithine76552424856599957452326Taurine79798017100132513211232752247540192271193781746α-amino-butyric acid77728564350253832355448223524254442422353[^2]Fig. 1Visualization of amino acid excretion in Hartnup disorder.A) Heatmap of amino acid excretion values. Normal excretion values are depicted in blue, and excretion values higher than age-adjusted upper reference values are depicted in red. White indicates that excretion values of that amino acid were not quantified. B) Heatmap of the fold changes of the urinary amino acid concentrations over the age-adjusted upper reference value, allowing visual differentiation of Hartnup disorder from generalized aminoaciduria, lysinuric protein intolerance and cystinuria. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 1

We assessed whether the degree of increase could aid differentiation of Hartnup disorder from other aminoacidurias. Indeed, quantification of amino acid excretion values and computation of amino acid fold changes enabled visual discrimination between Hartnup disorder and generalized aminoaciduria ([Fig. 1](#f0005){ref-type="fig"}B). The heatmap demonstrating the fold changes shows that, unlike in patients with generalized aminoaciduria, in both Hartnup disorder cohorts the fold changes of HAA were strikingly higher than the fold changes of OAA. LPI and cystinuria could also be recognized easily: LPI based on clear increases of arginine, lysine and ornithine and cystinuria based on the additional increase of cystine ([Fig. 1](#f0005){ref-type="fig"}B).

In patients with Hartnup disorder, the mean fold change of HAA ranged from 8.1 for phenylalanine to even 49.7 for valine. Histidine, an amino acid classically related to Hartnup disorder, was unexpectedly only slightly elevated, with a mean fold change of 3.1. Surprisingly, this was even lower than in generalized aminoaciduria, for which a mean fold change of 7.8 was calculated. Histidine excretion, while increased in 18/20 samples, seemed similar to the excretion of OAA (range mean fold change 0.9--13.1). Computation of the ratio of the mean fold change of HAA over OAA (including histidine) clearly distinguished Hartnup disorder from other aminoacidurias ([Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}A). The mean HAA/OAA ratio in the Hartnup cohort was 6.1, whereas the mean HAA/OAA ratio in the aminoaciduria cohort was only 0.2 (Mann-Whitney test *p* \< .0001). Moreover, no overlap was observed between the two cohorts, as the minimum value of the HAA/OAA ratio in Hartnup disorder was 2.4, while the maximum value of the HAA/OAA ratio in other aminoacidurias was 1.6 ([Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}A).Table 2HAA/OAA ratio and Ala/(Gly + His) ratio in Hartnup disorder versus other aminoacidurias.Table 2PatientsSamplesFULL RATIO: HAA/OAALIMITED RATIO: ALA/(GLY + HIS)Mean FC HAAMean FC OAAHAA/OAA ratio (mean (range))FC AlanineMean FC Gly and HisAla/(Gly + His) ratio (mean (range))Hartnup disorder -- Utrecht42019.73.76.1 (3.1--9.2)10.52.54.2 (2.7--9.8)Hartnup disorder -- Potter et al.7712.01.96.2 (2.4--9.6)11.92.54.7 (4.0--6.2)Hartnup disorder -- Combined**112717.73.26.1 (2.4--9.6)10.92.54.3 (2.7--9.8)**Generalized aminoaciduria7107.26.21.0 (0.5--1.6)**4.77.20.7 (0.4--1.3)**Lysinuric protein intolerance2161.610.50.2 (0.1--0.5)2.51.71.8 (1.0--3.5)Cystinuria7421.237.00.0 (0.0--0.1)0.71.60.6 (0.2--1.7)Aminoaciduria -- Combined**16682.325.70.2 (0.0--1.6)**1.82.60.9 (0.2--3.5)[^3][^4]Fig. 2HAA/OAA ratio and Ala/(Gly + His) ratio in Hartnup disorder versus other aminoacidurias.The Hartnup disorder cohort from Utrecht is depicted in orange, the Hartnup disorder cohort of Potter et al. is depicted in brown. Generalized aminoaciduria is depicted in green, lysinuric protein intolerance is depicted in blue and cystinuria is depicted in magenta. The error bar depicts the minimum and maximum values of the presented group. A) The y-axis depicts the HAA/OAA ratio. The x-axis distinguishes patients with Hartnup disorder from patients with other aminoacidurias. The dashed line at ratio = 2 depicts the cut-off value between Hartnup disorder and other aminoacidurias. B) The y-axis depicts the Ala/(Gly + His) ratio. The x-axis distinguishes the five patient groups. The dashed line at ratio = 2 depicts the cut-off value between Hartnup disorder and generalized aminoaciduria. Abbreviations: Ala: alanine; FC: fold change; Gly: glycine; HAA: Hartnup amino acids; His: histidine; OAA: other amino acids. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2

Computation of the HAA/OAA ratio required quantification of all included amino acids ([Table 2](#t0010){ref-type="table"}). Acknowledging that this is not standard practice in many metabolic diagnostic laboratories, we also evaluated the performance of a ratio using a limited set of amino acids, specifically aiming to distinguish Hartnup disorder from generalized aminoaciduria. Only six amino acids were quantified in all samples of patients with generalized aminoaciduria: serine, alanine, glycine, histidine, cystine and lysine. Of these amino acids, the differences in fold changes between these two patients groups were the largest for alanine, glycine and histidine. The ratio of the fold change of alanine over the mean fold change of glycine and histidine clearly discriminated Hartnup disorder from generalized aminoaciduria, with a mean Ala/(Gly + His) ratio in the Hartnup cohort of 4.3, contrasting with a mean Ala/(Gly + His) ratio of only 0.7 in the generalized aminoaciduria cohort. Even for this limited ratio, there was no overlap between the two cohorts, as the minimum value in the Hartnup cohort was 2.7, while the maximum value for the ratio in generalized aminoaciduria was 1.3 ([Table 2](#t0010){ref-type="table"}, [Fig. 2](#f0010){ref-type="fig"}B).

4. Discussion {#s0035}
=============

In this study we demonstrated that quantitative assessment of the degree of the increases, rather than qualitative assessment of increases of amino acid excretion, enhances correct discrimination of Hartnup disorder from other aminoacidurias. We introduce the HAA/OAA ratio as a new and easily applicable diagnostic tool to discriminate Hartnup disorder from other aminoacidurias. Moreover, we demonstrate that even the limited Ala/(Gly + His) ratio, requiring quantification of only three amino acids, can distinguish Hartnup disorder from generalized aminoaciduria.

Quantification of all urinary amino acid concentrations revealed that, in addition to the amino acids reported to be excreted excessively in Hartnup disorder (Nanto-Salonen et al. 2006, Vademecum Metabolicum), cystine, alpha-aminobutyric acid, glycine, lysine, citrulline, glutamic acid, aspartic acid and arginine can be increased as well in the urine of patients with Hartnup disorder \[[@bb0010],[@bb0015],[@bb0030]\]. Unexpectedly, the excretion of histidine, an amino acid of which the intestinal uptake and tubular reabsorption is expected to be affected (Nanto-Salonen et al. 2006, Vademecum Metabolicum), was increased only modestly in 18/20 samples, contrasting with the extent of the excretion of HAA. Whether the complete range of amino acids excreted by patients with Hartnup disorder can be explained by a broader substrate specificity of the B^0^ AT1 transporter than currently described, or whether the aberrant transport of amino acids in the proximal tubule of patients with Hartnup disorder affects (saturation of) other amino acid transporters remains to be elucidated.

It is of interest that the Hartnup disorder cohort derived from Potter et al. described a less generalized aminoaciduria in their patients, even though the same reference values were used. We speculate that differences in the patient age at time of sampling (all adults in Potter et al.) may affect the amino acid excretion pattern. Moreover, differences in nutrition, particularly a higher protein intake, could have contributed to the here observed more pronounced generalized aminoaciduria \[[@bb0015]\]. Still, despite these differences, the distribution of the calculated ratios is comparable, corroborating the accuracy of these ratios in discriminating Hartnup disorder from other aminoacidurias. However, given the relatively small sample sizes of the two cohorts, it would be of interest to assess the generalizability of the calculated ratio in another, independent cohort of patients with Hartnup disorder.

As nutritional intake, including protein intake, has been increasing in many countries over the past decades \[[@bb0015]\], the degree to which individuals with Hartnup disorder demonstrate amino acid excretion patterns mimicking generalized aminoaciduria might increase as well, explaining why quantification of urinary amino acid concentrations was not required in the past, but is expedient now.

In conclusion, we here report that excretion values of amino acids not classically related to Hartnup disorder, are frequently elevated in patients with Hartnup disorder. This may induce a risk of misdiagnosis as generalized aminoaciduria and preclusion from vitamin B3 treatment. By changing the focus from absolute to relative increase of amino acid excretion and by calculating the HAA/OAA ratio, we introduce a diagnostic tool that enhances correct discrimination of Hartnup disorder from other aminoacidurias.

Take home message {#s0040}
=================

The fold change ratio of Hartnup amino acids over other amino acids ensures correct diagnostic differentiation of Hartnup disorder from other aminoacidurias.
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